Treatment of breast cancer with a parp inhibitor alone or in combination with Anti-tumor agents

a technology of breast cancer and parp inhibitor, which is applied in the direction of drug composition, sexual disorder, therapy, etc., can solve the problems of difficult variants of breast cancer, no accepted standard of care for er negative breast cancer, and limited treatment of anthracycline, so as to reduce the size of breast tumor, improve clinical benefit rate, and reduce the effect of metastasis

Inactive Publication Date: 2010-01-07
BIPAR SCI INC
View PDF103 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, while about 70% of breast cancers are ER positive, the remaining 30% of breast cancers that are HR negative are not amenable to treatment with SERMs.
Treatment with anthracycline is limited by lifetime dosing limits based on cardiotoxicity concerns.
Despite the availability of antimetabolites such as gemcitabine and platinum complex agents such as carboplatin, there is no accepted standard of care for ER negative breast cancer.
In particular, triple negative metastatic breast cancer (i.e. breast cancer that is ER negative, and / or PR negative, and / or human epidermal growth factor receptor 2 (HER2) negative) is refractory to standard treatments and is entirely refractory to SERM chemotherapy.
Although there are limited therapeutic options for cancer treatment, variants of cancers, including triple negative breast cancer, are especially difficult because they can be refractory to standard chemotherapeutic or hormonal treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of breast cancer with a parp inhibitor alone or in combination with Anti-tumor agents
  • Treatment of breast cancer with a parp inhibitor alone or in combination with Anti-tumor agents
  • Treatment of breast cancer with a parp inhibitor alone or in combination with Anti-tumor agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

PARP1 Expression in IDC Breast Cancer

[0232]Previous studies have shown increased PARP activity in ovarian cancers, hepatocellular carcinomas, and rectal tumors, compared with normal healthy control tissues, as well as in human peripheral blood lymphocytes from leukemia patients (Yalcintepe L, et. al. Braz J Med Biol Res 2005;38:361-5. Singh N. et. al. Cancer Lett 1991;58:131-5; Nomura F, et. al. J Gastroenterol Hepatol 2000;15:529-35). This invention uses the gene expression databases to examine PARP1 gene regulation in more than 2000 primary malignant and normal human tissues. While PARP1 expression and activity is very low and uniform across the majority of normal human tissues and organs, it is upregulated in selected tumor cells and primary human malignancies, with the most striking differences found in breast, ovarian, lung, and uterine cancers (FIG. 1).

Tissue Samples

[0233]Specimens are harvested as part of a normal surgical procedure and flash frozen within 30 minutes of resec...

example 2

Combination of 4-iodo-3-nitrobenzamide (BA) with chemotherapy

Cell Culture

[0240]Breast cancer cells are obtained from ATCC and cultured in Dulbecco Modified Eagle Medium with 10% fetal bovine serum. Cells are plated at 105 cells per P100 cell culture dish or at 104 cells per P60 cell culture dish in the presence of different concentrations compounds or DMSO control. Following treatment, the number of attached cells is measured using Coulter counter, and by staining with 1% methylene blue. Methylene blue is dissolved in 50%-50% mixture of Methanol and water. Cells are plated in 24- or 96-well plates and treated as planned, media are aspirated, cells are washed with PBS, fixed in methanol for 5-10 min, methanol is aspirated and plates are allowed to dry completely. Methylene blue solution is added to wells and plates are incubated for 5 min. Staining solution is removed and plates are washed with dH2O until washes are no longer blue. After plates are completely dry, a small amount of 1...

example 3

Combination of 4-iodo-3-nitrobenzamide (BA) with irinotecan

[0248]Breast cancer cells are obtained from ATCC and cultured in Dulbecco Modified Eagle Medium with 10% fetal bovine serum. Cells are plated at 105 cells per P100 cell culture dish or at 104 cells per P60 cell culture dish in the presence of different concentrations compounds or DMSO control. Following treatment, the number of attached cells is measured using Coulter counter, and by staining with 1% methylene blue. Methylene blue is dissolved in 50%-50% mixture of Methanol and water. Cells are plated in 24- or 96-well plates and treated as planned, media are aspirated, cells are washed with PBS, fixed in methanol for 5-10 min, methanol is aspirated and plates are allowed to dry completely. Methylene blue solution is added to wells and plates are incubated for 5 min. Staining solution is removed and plates are washed with dH2O until washes are no longer blue. After plates are completely dry, a small amount of 1N HCl is added...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
temperatureaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.

Description

CROSS REFERENCE[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 987,333, entitled “Treatment of Triple Negative Metastatic Breast Cancer with a Combination of an Antimetabolite, a Platinum Complex, and a PARP Inhibitor” filed Nov. 12, 2007 (Attorney Docket No. 28825-742.101); U.S. Provisional Application No. 61 / 012,364, entitled “Treatment of Cancer with Combinations of Topoisomerase Inhibitors and PARP Inhibitors” filed Dec. 7, 2007 (Attorney Docket No. 28825-747.101); and U.S. Provisional Application No. 61 / 058,528, entitled “Treatment of Breast, Ovarian, and Uterine Cancer with a PARP Inhibitor” filed June 3, 2008 (Attorney Docket No. 28825-757. 101), each of which applications is incorporated herein in its entirety by reference.BACKGROUND[0002]Cancer is a group of diseases characterized by aberrant control of cell growth. The annual incidence of cancer is estimated to be in excess of 1.3 million in the United States alone. While surgery, radiation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K51/04A61P35/00A61K101/02
CPCA61K31/166A61K31/282A61K31/7068A61K41/00A61K45/06A61K31/00A61K31/337A61K31/555A61K2300/00A61P15/00A61P15/14A61P35/00A61P35/04A61P43/00
Inventor SHERMAN, BARRY M.BRADLEY, CHARLESOSSOVSKAYA, VALERIA S.
Owner BIPAR SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap